This Month’s Focus: Instruments
Resolving a few misconceptions when analyzing data from inhaler particle size distribution measurements
This article discusses important misconceptions that from-time-to-time have appeared concerning the analysis of particle size data. It primarily focuses on multi-stage cascade impaction, which is the primary technique for OIP APSD measurement. However, attention is also paid to the analysis of size distribution data from time-of-flight analyzers and laser diffractometer instruments that are also encountered in the evaluation of inhaler performance, particularly the latter for the assessment of nasal products.
New perspectives on the microstructure of inhalable formulations through laboratory 3-D X-ray microscopy
Unanswered questions relating to pre-aerosolized formulations include (1) What does the blend formulation truly look like? (2) How do different parts of the blend interact with each other? (3) How do we quantify the microstructure? 4) How does the microstructure change due to manufacturing processes or storage? This article explores how X-ray microscopy can offer new insights into the microstructure of inhalable formulations for dry powder inhalers. The findings are part of the INFORM2020 collaboration.
General Features
Back Page: United States national asthma guidelines receive first update since 2007
The guidelines for prescribing, testing and management of asthma have been updated by the National Asthma Education and Prevention Program (NAEPP) Coordinating Committee, coordinated by the National Heart, Lung, and Blood Institute (NHLBI) of the US National Institutes of Health (NIH). The update is not a complete revision of the prior guidelines but focuses on six topics including inhaled corticosteroids (ICS) and long-acting muscarinic antagonists (LAMA).
Cross-Industry Organizations: ISAM: 2020 highlights and a preview of the 2021 Congress
Throughout 2020, the ISAM board, members and scientists served as experts in the scientific community, providing guidance and scientific consultation, hosting webinars and authoring peer-reviewed literature. To provide science-based information in the area of COVID-19, ISAM dedicated a portion of its website to the topic and made it available for members and non-nonmembers. The article also previews the 2021 Congress, which is designed to be both a live and virtual event.
June Content
Exploring new pMDI propellants for a greener future
How critical quality attributes of the drug substance can support OINDP quality
Cross-Industry Organizations: IPAC-RS and a conversation with the US FDA: Perspectives in the time of COVID-19
Issue Focuses
January: Reference and Buyer’s Resource
February: Product Development/ Contract Testing
April: Instruments
June: Nasal Delivery/Nebulizers
August: Particle Characterization
October: Devices
December: Quality/Compliance
Vicki Schuman
1155 Northland Drive
St. Paul, MN 55120
651-287-5600
Fax 651-287-5650
vschuman@cscpub.com
Inhalation Article Guidelines
Technical article requirements
The article should be technical and educational, but not promotional. It must be new, not previously published and must be at least 50% different from your previous articles or other articles you are simultaneously developing on the same subject.
All discussions of products or technologies must be in an unbiased, non-promotional, educational manner. If your article discusses products that have been commercialized or are in development, please be aware of the following: Inhalation takes a very limited approach in discussing products, usually listing only product name, delivered drug name and company name, unless a description is provided by the particular company that owns a product, such as in a case study article or product news release. In that way, each company can choose the information it wishes to discuss or disclose about its own products, rather than being discussed by an outside party with no ability to comment prior to publication. However, if an article is a case study, presentation of a novel technology or news article written by the owner company or its representative such as a scientist or consultant, we are happy to consider all information or data they wish to disclose, provided it is presented in a fair-balanced manner. Also, please avoid discussing product or development costs and do not make cost comparisons.
The article should be 2,500-3,500 words and must include at least five references or items for recommended reading.
We encourage images and/or data tables and have space for three or four of them. We’re flexible about that number so let us know if you need more image space. We also like to publish an additional photo or illustration at the beginning of the article. Images should be sent as separate files that meet the following specifications: high resolution, 300 dpi at a size of 7 x 7 inches and in only JPG, TIF or EPS formats.
Please be aware, due to copyrights, if you use figures or tables from articles that have been previously published in other journals, you must obtain permission from those journals in order to use the images. If you are an author on the published article in question, you may still need permission but there should be no fees from the other journal. If you are not an author and the other journal wants to charge you fees for usage, please contact us before proceeding. We do not want authors incurring costs in order to publish in Inhalation and there may be alternate approaches to citing information that could be used. Also, “open journals” do not charge for image use. If you have any questions or concerns, please contact us.
Editorial board review and production
All of our articles are peer-reviewed and must be accepted by our editorial board or a designated reviewer in order to be published. When you send us the article, it will go to a member of the board and we will coordinate communication between you. Once an article is accepted, we handle production and you will see the final article in layout before it goes to print or is published in the digital edition.
Contract Testing
Excipients
